膀胱癌患者血及肿瘤组织尿激酶含量的检测

　　摘要　目的　了解尿激酶型纤溶酶原激活剂（uPA）与膀胱肿瘤恶性程度及浸润深度之间的关系。　方法　采用酶联免疫吸附实验（ELISA）检测51例膀胱移行细胞癌病人术前、术后静脉血及肿瘤组织uPA含量。　结果　G3肿瘤组织uPA含量明显高于G1和G2（P均＜0.01），G1与G2间uPA差异无显著性；浸润癌肿瘤组织uPA含量明显高于表浅肿瘤组织（P＜0.05）。病人术前及术后静脉血uPA含量与正常人静脉血uPA含量差异无显著性。　结论　肿瘤组织uPA含量可以反映膀胱肿瘤的恶性程度和肿瘤浸润深度。

Urokinase-type plasminogen activator (uPA) in the neoplastic tissue and peripheral blood of bladder cancer patients

YANG Jinyi,LI Shao,ZhOU Rongxiang,et al.

　　Department of Urology,the Affiliated Hospital of Binzhou Medical College, Shandong 256603

　　Abstract　Objective　To study the uPA level in the neoplastic tissue and peripheral blood of bladder cancer patients.　Methods　51 cases of transitional cell bladder cancer were studied by means of enzyme-linked immunosorbent assay (ELISA).　Results　uPA content in neoplastic tissue of grade Ⅲ tumors was obviously higher than that in grade Ⅱ or grade Ⅰ tumors

[1] [2] [3] [4] [5]